Sign up to save your podcasts
Or
Share Ozempic Made Novo Nordisk a Giant. Here's Why It's Stock Might Be Undervalued
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ozempic Made Novo Nordisk a Giant. Here's Why It's Stock Might Be Undervalued
Ozempic’s still the hottest drug on the planet.
But Novo Nordisk’s stock? Not so much. It’s down nearly 50% from its peak, and investors aren’t sure whether to double down or walk away.
In today’s episode, Finimize Analyst Russell Burns, whose latest research unpack's what’s really going on with the stock, joins the pod.
Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking?
Try Finimize Pro
View all episodes
By FinimizeOzempic’s still the hottest drug on the planet.
But Novo Nordisk’s stock? Not so much. It’s down nearly 50% from its peak, and investors aren’t sure whether to double down or walk away.
In today’s episode, Finimize Analyst Russell Burns, whose latest research unpack's what’s really going on with the stock, joins the pod.
Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking?
Try Finimize Pro